Derin Colvin
Psychiatric/Mental Health · Beaverton, ORNPI 1346989944
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 249 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 21.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $3,127 and has fallen 94.6% since, to $168 in 2025. Among psychiatric/mental health clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 249 payments — averaging $20.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$1K
- AbbVie$513
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$503
- Corium, LLC$481
- Otsuka America Pharmaceutical, Inc.$426
- Lundbeck LLC$385
- plus $2K from 18 others
What the payments were for
- Food & beverage$5,06199%
- Education$611%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 40 | $1,077 |
| AbbVie | 36 | $513 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 24 | $503 |
| Corium, LLC | 23 | $481 |
| Otsuka America Pharmaceutical, Inc. | 25 | $426 |
| Lundbeck LLC | 16 | $385 |
| Alkermes, Inc. | 12 | $261 |
| Axsome Therapeutics, Inc. | 11 | $239 |
| Neurocrine Biosciences, Inc. | 9 | $205 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $172 |
| Almatica Pharma LLC | 9 | $168 |
| Tris Pharma Inc | 6 | $144 |
| Vanda Pharmaceuticals Inc. | 5 | $109 |
| Vertical Pharmaceuticals, LLC | 4 | $77 |
| Ironshore Pharmaceuticals Inc. | 3 | $72 |
| Johnson & Johnson | 3 | $62 |
| Teva Pharmaceuticals USA, Inc. | 4 | $61 |
| Idorsia Pharmaceuticals US Inc | 3 | $50 |
| Avion Pharmaceuticals | 1 | $24 |
| Biogen | 1 | $23 |
| Tempus AI, Inc | 1 | $19 |
| Sunovion Pharmaceuticals Inc. | 1 | $18 |
| Harmony Biosciences LLC | 1 | $18 |
| Noven Therapeutics, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,122 in reported general payments places this provider in the 95th percentile of 540 psychiatric/mental health providers in Oregon.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Duloxetine Hcl | 18 | $960 |
| Bupropion XlBupropion Hcl | 16 | $422 |
| Lamotrigine | 13 | $351 |
| Quetiapine Fumarate | 13 | $287 |
| Clonazepam | 11 | $82 |
| Trazodone Hcl | 13 | $61 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Beaverton
- Amber HobergHillsboro$1.9M
- Tina Matthews-HayesPortland$787K
- Carmen KosicekHillsboro$539K
- Johnni CanslerPortland$529K
- Jill CarterPortland$416K
- William BettsEugene$41K
- Michelle VoegelsPortland$29K
- Rance SmithKlamath Falls$15K
- Jennifer BehnkeMcMinnville$14K
- Susan EllisRoseburg$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.